

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 February 2004 (12.02.2004)

PCT

(10) International Publication Number
WO 2004/013054 A1

- (51) International Patent Classification⁷: C02F 3/34, C07K 16/12, C12N 9/00
- (21) International Application Number: PCT/EP2003/007495
- (22) International Filing Date: 10 July 2003 (10.07.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 0217417.5 27 July 2002 (27.07.2002) GB
- (71) Applicant (for all designated States except US): **THE QUEEN'S UNIVERSITY OF BELFAST** [GB/GB]; University Road, Belfast BT7 1NN, Northern Ireland (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **LARKIN, Michael, James** [GB/GB]; Queen's University of Belfast, University Road, Belfast BT7 1NN, Northern Ireland (GB). **CONNER, Nichola, Louise** [GB/GB]; Queen's University of Belfast, University Road, Belfast BT7 1NN, Northern Ireland (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: A METHOD OF CONTROLLING MICROTHRIX PARVICELLA PROLIFERATION OF WASTE TREATMENT PLANTS

(57) Abstract: A method of controlling Microthrix parvicella proliferation in a waste treatment plant comprises the step of inactivating one or more Microthrix parvicella growth factors in the waste, wherein the growth factors are selected from the group consisting of: gamma-butyrolactone and Rpf protein. The or each growth factors is inactivated by including in the waste a bacterial isolate which uses the or each growth factor as a carbon source and/or nitrogen source, typically a sole carbon source. Alternatively, one or more of the growth factors may be inactivated by adding to the waste an enzyme preparation which functions to specifically cleave the or each growth factor. Suitably, an antibody preparation, which includes one or more antibodies which specifically target and inactivate one or more of the growth factors, is included in the waste being treated. A composition for carrying out the methods of the invention is also described.



WO 2004/013054 A1

A METHOD OF CONTROLLING MICROTHRIX PARVICELLA PROLIFERATION OF WASTE TREATMENT
PLANTS

1

2

3

4 Introduction

5

6 This invention relates to a method of controlling
7 the proliferation of *Microthrix parvicella* in waste
8 treatment plants, and particularly in activated
9 sludge waste treatment plants.

10

11 "Microthrix parvicella" is a filamentous bacterium,
12 belonging to the order Actinomycetales. This
13 bacterium is the major causative organism of bulking
14 and foaming in activated sludge waste-water
15 treatment plants in Europe (Eikelboom, 1977;
16 Rossetti et al, 1994; Kristensen et al, 1994),
17 Australia (Seviour et al, 1994), South Africa
18 (Blackbeard et al, 1986), and the USA (Richard et
19 al, 1982). This organism is frequently found in vast
20 numbers in waste treatment systems, where it causes
21 solids separation problems. This problem is
22 manifested as several major operational problems

1 that can have serious environmental and economic
2 repercussions. These include; reduced final effluent
3 quality (through poor settling i.e., bulking, which
4 in turn leads to worsened effluent quality due to
5 loss of biomass, which normally reduces carbonaceous
6 matter, and BOD levels); quantity of solids going to
7 landfill or for incineration; load exertion on pumps
8 and a potential biohazard through the production of
9 foams, containing high numbers of potentially
10 pathogenic bacteria which can aerosolise. These
11 problematic manifestations can readily result in the
12 affected waste-water treatment plant in question
13 failing to meet the effluent standards set by the
14 relevant government authorities. In some countries,
15 financial penalisation for the plant operator can be
16 costly.

17
18 One of the major issues that has been raised
19 regarding the proliferation of this microorganism is
20 it's extremely slow-growth when in pure laboratory
21 culture. This is in stark contrast to the apparent
22 abundance of the organism in waste treatment systems
23 encountering a *Microthrix parvicella*-induced bulking
24 event.

25
26 The concept of cell-cell signalling among bacteria
27 is now a generally accepted phenomenon. Since the
28 1960's, the role of N-acyl homoserine lactones
29 (AHL's) as quorum-sensing molecules has been
30 observed amongst many species of Gram-negative
31 bacteria. More recently, it has come to light that
32 signalling molecules may play a role in the growth

1 of Gram-positive bacteria (such as the
2 Actinomycetales). The signalling molecules which may
3 affect the onset of secondary metabolism processes
4 and the growth characteristics of the
5 Actinomycetales are comprised of a family of
6 compounds containing a gamma -butyrolactone ring
7 (similar to the AHL's) and small proteins regarded
8 as Rpf-like proteins (resuscitation promoting
9 factor-like proteins).

10

11 Amongst the genus *Streptomyces*, the most widely
12 studied gamma-butyrolactone-containing molecule is
13 A-Factor (2-isocapryloyl-3R-hydroxymethyl-gamma-
14 butyrolactone). This molecule, and a range of other
15 butyrolactone-containing compounds (acylated at the
16 C3 position with acyl moieties of variable size and
17 composition), do not affect growth rate but markedly
18 affect secondary metabolism events involved in
19 morphogenesis (Nodwell and Losick, 1996) and
20 antibiotic production (Bibb, 1996). A-factor is a
21 low molecular weight regulatory compound produced by
22 *S. griseus* which induces antibiotic production and
23 sporulation. The compound is notable in that it is
24 effective in extremely low concentrations in the nM
25 range (Horinouchi and Beppu, 1992).

26

27 The other group of signalling molecules noted for
28 some members of this group of bacteria are the Rpf-
29 like proteins. The Rpf protein was discovered as a
30 factor produced by actively growing *Micrococcus*
31 *luteus* cells, which, in picomolar concentrations,
32 will resuscitate "dormant" cells which have

1 undergone a period of starvation (Mukamolova et al,
2 1998). Again the effect is not noted to increase
3 growth rate per se. The protein is ~ 17kDa in size
4 and more recently, genes encoding proteins similar
5 to Rpf have been found throughout a cohort of
6 Actinomycetes, including *Mycobacterium tuberculosis*,
7 *M. leprae*, *M. bovis*, *M. smegmatis*, *Corynebacterium*
8 *glutamicum* and several species of *Streptomyces*
9 (Mukamolova et al, 1998).

10

11 Current control strategies for *Microthrix parvicella*
12 -induced activated sludge bulking involves some of
13 the following methods. The addition of chemical
14 chelating agents, polyelectrolytes, which act by
15 physically sequestering activated sludge flocs, thus
16 enhancing the compaction and sedimentation rate of
17 the activated sludge. Oxidising agents such as
18 permanganate and chlorine may be used to "bleach"
19 the whole sludge biomass. Operational conditions may
20 be altered to waste higher volumes of sludge,
21 thereby reducing the total biomass in the system.
22 The problem with these methods for controlling
23 sludge bulking is that they are not only empirical,
24 but extremely non-specific. Indeed, the use of
25 aggressive oxidising agents or "bleaches" not only
26 "kills off" the majority of the biomass, but also
27 results in elevated doses of these agents in the
28 resulting effluent. The use of polyelectrolytes does
29 not remove *Microthrix*, the causative organism, and
30 it is returned to the oxidation ditch with the
31 return activated sludge (RAS).

32

1 It is an object of the invention to overcome at
2 least some of the above problems by specifically
3 targeting molecules that are growth factor and
4 enhance the growth of *Microthrix parvicella*.
5

6 Statements of Invention
7

8 According to the invention, there is provided a
9 method of controlling *Microthrix parvicella*
10 proliferation in a composition, suitably waste in a
11 waste treatment plant, comprising the step of
12 inactivating one or more *Microthrix parvicella*
13 growth factors in the composition, wherein the
14 growth factors are selected from the group
15 consisting of: gamma-butyrolactone and Rpf protein.
16 In this specification, the term "inactivating"
17 should be understood to include degrading, cleaving,
18 chemically modifying, and other means of rendering
19 the growth factor inactive. The term "gamma-
20 butyrolactone" should be understood to include
21 gamma-butyrolactone containing molecules and related
22 compounds such as those having a butyrolactone ring.
23 The term "Rpf protein" should be understood to
24 include Rpf-like proteins. The term "composition"
25 should be understood as primarily relating to a
26 waste in a water treatment plant, however it should
27 not be restricted to this meaning. As such, the
28 method of the invention could be equally applied to
29 the treatment of seawater, fresh water, rivers,
30 lakes, canals, resevoirs etc.

31

1 Thus, in one embodiment of the invention, one or
2 more of the growth factors may be inactivated by
3 including in the waste a bacterial isolate which
4 uses one of the growth factors as a carbon source
5 and/or nitrogen source, typically a sole carbon
6 source. Bacterial strains which use gamma-
7 butyrolactone as a carbon source are likely to occur
8 commonly in nature and may be selected from the
9 group of bacteria including *Mycobacterium vaccae*
10 which grows on gamma-butyrolactone (Hamamura et al,
11 1999) and isolated strains such as *Rhodococcus*
12 rhodochrous NCIMB 13064 which utilises this compound
13 as a sole carbon source (Curragh et al, 1994) and
14 other similar strains isolated from waste-water
15 treatment systems. Bacterial strains which use
16 peptides as carbon and nitrogen source through the
17 action of protease enzymes are very common in nature
18 (Rao and Deshpande 1998). Bacterial strains that
19 utilise Rpf protein as a carbon and or nitrogen
20 source may be selected from a wide variety of these
21 known protease producing bacterial strains.
22 Typically, a combination of bacterial isolates
23 selected from the one or more of the above two
24 groups may be added to the waste.

25

26 In an alternative embodiment of the invention, or in
27 addition to the above, one or more of the growth
28 factors may be inactivated by adding to the waste an
29 enzyme preparation which functions to specifically
30 cleave the or each growth factor. Non specific and
31 or specific microbial proteases to cleave Rpf and
32 Rpf-like proteins could be used in conjunction with

1 esterases to reverse the internal cyclic structure
2 of the gamma-butyrolactone ring and thus inactivate
3 it. A further possible method of inactivating one
4 or more of the growth factors is to include in the
5 waste, antibodies which specifically target and
6 inactivate one or more of the growth factors. Such
7 antibodies may be monoclonal or polyclonal
8 antibodies. Antibody production is a commonly known
9 methodology (Heddy Zola, 2000) and has been applied
10 to detect specific microorganisms in waste-waters
11 (e.g. Brigmon et al, 1995). The technique of
12 developing monoclonal antibodies to very
13 specifically bind to and detect small molecules in
14 water samples is established (Knopp, 1995) and has
15 been developed further by use of the phage display
16 technique for the production of antibodies (Hall et
17 al 1997). Monoclonal antibodies have been
18 developed, for example, to specifically bind to, and
19 thus detect, small molecules as chemical pollutants;
20 for example hormone disrupting chemicals such as
21 estrogen and related molecules (Goda et al, 2000).
22 The sensitivity of this method with respect to such
23 small molecules has been improved by coupling the
24 antibodies to magnetic particles (Matsunaga et al,
25 2003). Such methodology could be employed to bind
26 to and remove or inactivate the target molecules
27 that act as growth factors for *Microthrix*
28 *parvicella*.
29
30 Chemical selectors may be employed to inactivate the
31 gamma-butyrolactone based on chemical modification
32 of the gamma-butyrolactone ring. Areas or

1 "selectors", typically upstream from the main
2 aeration basin of a waste-water treatment plant,
3 which provide conditions that favour such
4 modification would be employed. These conditions
5 could include excess hydroxyl (OH^-) ions (for
6 example, by increasing the pH) to incur hydroxide
7 ion catalysis of the internal ester bond.
8 Alternatively, by introducing either an acid or a
9 base (alkali), general acid or general base
10 catalysis of the ester bond would occur, by
11 attacking the bond from the slightly negatively
12 charged oxygen atom or the slightly positively
13 charged carbon atom, respectively. These chemical
14 modifications would inactivate the factor and result
15 in the production of a linear carboxylic acid.

16

17 The invention also relates to a composition for
18 inactivating *Microthrix parvicella* growth factors
19 comprising one or more inactivating agents selected
20 from the group consisting of:

21 a bacterial preparation which uses the growth factor
22 as a carbon and/or nitrogen source, typically a sole
23 carbon source; an enzyme preparation which
24 specifically cleaves the growth factor; and an
25 antibody preparation which specifically targets and
26 inactivates the growth factor,
27 wherein the at least one growth factor is selected
28 from the group consisting of: gamma-butyrolactone
29 and Rpf protein.

30

31 The invention also relates to a composition for
32 inactivating *Microthrix parvicella* growth factors

1 consisting essentially of one or more inactivating
2 agents selected from the group consisting of:
3 a bacterial preparation which uses the growth factor
4 as a carbon source, typically a sole carbon source;
5 an enzyme preparation which specifically cleaves the
6 growth factor; and an antibody preparation which
7 specifically targets and inactivates the growth
8 factor, wherein the at least one growth factor is
9 selected from the group consisting of: gamma-
10 butyrolactone and Rpf protein. Any combination of
11 the above mentioned inactivating agents is
12 envisaged.

13

14 The invention also relates to the use of a
15 composition according to the invention in waste
16 treatment plants to control the proliferation of
17 *Microthrix parvicella*.

18

19 It is reasonable to suggest that both Rpf-like
20 proteins and A-factor and A-factor homologues will
21 be present in these waste treatment systems as the
22 producing organisms are likely to present in the
23 highly heterogeneous culture mix. Furthermore, they
24 are known to be effective at extremely low
25 concentrations. It has been shown that gamma-
26 butyrolactone is produced as an end product
27 metabolite resulting from the aerobic β -oxidation of
28 chlorinated fatty acids (Curragh et al, 1994). Such
29 substrates and this type of metabolic pathway occur
30 in many waste treatment systems. Moreover,
31 *Microthrix parvicella* has been associated with waste
32 treatment systems loaded with high levels of fatty

1 acids (Andreasen and Neilsen, 1998); many of which
2 are likely to be chlorinated due to the extensive
3 use of hypochlorite disinfectants.

4
5 In light of the growing evidence of factors which
6 can have effects at low concentrations on a number
7 of the members of the Actinomycetales (of which
8 *Microthrix parvicella* is a member), the effect of
9 gamma-butyrolactone, and sterile, spent culture
10 supernatants from growing cells which produce these
11 compounds, as well as Rpf protein, has been
12 investigated using *Microthrix parvicella* laboratory
13 cultures to establish that these alone and in
14 combination may enhance growth.

15

16 Detailed Description of the Invention

17

18 The invention will be more clearly understood from
19 the following description of some embodiments
20 thereof, given by way of example only.

21

22 Materials and Methods

23

24 *Microthrix parvicella* RN1 (Rossetti et al. (1997)
25 was obtained from Dr. Valter Tandoi (Water Research
26 Institute, Rome). The growth medium (R2AM) used was
27 a modified form of R2A (Reasoner and Geldreich
28 (1985)), with the additions of (per litre medium):
29 $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$, 0.05g; cycloheximide, 20mg; NMS Trace
30 Elements (Atlas (1995)), vitamins (Eikelboom
31 (1968)). To test growth on sludge supernatants and
32 spent culture media, 10X R2AM was supplemented with

1 centrifuged sludge, filter sterilised (0.2µm),
2 (R2AMS) or filter sterilised (0.2µm) spent culture
3 supernatants from *M. luteus* (NCIMB 13267) and
4 *Streptomyces griseus* (NCIMB). Due to the paucity of
5 growth and the "clumpy" nature of the filamentous
6 bacteria, the organism was cultivated in sterile
7 microtitre plate wells (total volume of 150µl/well)
8 in the presence of a metabolic indicator, XTT
9 (Sigma) at a final concentration of 0.25mM. Optical
10 densities (620 nm) of wells were measured using SLT
11 Labinstruments (Austria) Microtitre Plate Reader.
12 Plates were incubated at 15°C (Knoop and Kunst,
13 1998).
14

15 Results and Discussion

16

17 The cell culture doubling times of *Microthrix*
18 *parvicella* in situ, were not determined directly,
19 but in batch culture, on R2AM medium (see materials
20 and methods). It can be seen in Table 1 that the
21 addition of low concentrations of gamma-
22 butyrolactone more than halved the cell doubling
23 times of *Microthrix* in pure culture. The addition of
24 sterilised spent culture supernatants from
25 *Micrococcus luteus* and *Streptomyces griseus* also
26 reduced the cell culture doubling times to less than
27 5 days. The control medium, R2AM, without addition
28 of any growth factor, is a complex medium in which
29 carbon sources would not be limiting (see materials
30 and methods). This yielded a cell culture doubling
31 time of >20days, however doubling times as long as

1 >100days have been observed on this medium in other
2 experiments (data not shown).

3

4 Table 1. Increase in growth rate observed as a
5 decrease in doubling times of *M. parvicella* in the
6 presence of gamma-butyrolactone and spent culture
7 supernatants containing Rpf (*M. luteus*) and A-factor
8 (*S. griseus*)

gamma- butyrolactone Concentration (mM)	Growth rate - Doubling Time (Days)
	R2AM medium
0	21
0.001	8
0.01	7
<i>M. luteus</i> spent culture supernatant	1-5
<i>S. griseus</i> spent culture supernatant	<2

9 It has been shown that the cell culture doubling
10 time of *Microthrix parvicella* is significantly
11 reduced (and thus growth rate increased) by the
12 addition of these growth factors to the pure culture
13 medium. These doubling times are equal to (and in
14 the case of *M. luteus* and *S. griseus* spent
15 supernatants, lesser than) the doubling times
16 observed when grown on R2AMS (see materials and
17 methods). Considering this data in the light of the

1 typical sludge age (roughly equivalent to the mean
2 cell residence time of around 10 days) in a waste
3 treatment plant which exhibits *Microthrix parvicella*
4 bulking (depending on temperature and weather), the
5 effect seen here would be the difference between a
6 *Microthrix parvicella* bulking event occurring or not
7 occurring.

8
9 A number of bacterial strains have been isolated
10 which have been shown to utilise gamma-butyrolactone
11 as a sole carbon source. Using the same method used
12 to obtain these organisms, other isolates can be
13 obtained which utilise A-factor Rpf and Rpf-like
14 factors. These organisms can be employed to degrade,
15 or "mop up", the signalling molecules in waste
16 treatment systems in a number of ways. For example,
17 ensuring a higher proportion of the growth factor
18 degrading microorganisms are present in waste
19 treatment plant will reduce the concentration of
20 signalling molecules. Alternatively, the
21 incorporation of "selectors" could be employed.
22 Selectors are compartmentalised areas within the
23 waste treatment system, usually upstream of the
24 aeration basin. These areas contain an environment
25 which should be unfavourable to adverse parameters
26 or microorganisms within the activated sludge. These
27 have previously been used to administer e.g.,
28 temperature shock, and regions of high
29 food/microorganism ratio (F/M ratio) in an attempt
30 to control bulking. By utilising this method in a
31 novel way, extremely high numbers of these bacteria
32 would be incorporated in selectors to degrade growth

1 factors in the input waste. Another control method
2 of the invention is to apply an enzyme preparation
3 to the waste treatment works. Using the isolates
4 obtained, an enzyme preparation can be obtained to
5 specifically cleave the signalling molecule in
6 question, thus effectively removing it from the
7 system. Specific antibodies can also be raised to
8 similarly target and inactivate the signalling
9 molecules. Using technology to raise specific
10 monoclonal and polyclonal antibodies to our
11 laboratory strain of *Microthrix*, antibodies which
12 have a high specific affinity to these molecules
13 could be administered, therefore blocking routes of
14 entry to the cell and subsequent attachment to
15 receptor proteins or target DNA.

16
17 There are a number of operational and economic
18 advantages to all of the above methods for
19 controlling *Microthrix* induced sludge bulking.
20 Current control methods are expensive: large volumes
21 of consumables (oxidising agents and
22 polyelectrolytes) are continually purchased. The
23 suggested methods here are inexpensive and are
24 largely self-renewable. Current methods are non-
25 specific, targeting all of the biomass, and also
26 inhibiting/killing the floc-forming bacteria in the
27 process. The method of the invention offers a much
28 higher degree of specificity. Previous methods
29 introduce toxic oxidising agents to the system and
30 result in elevated levels of these in the final
31 effluent; however, the methods of the invention

1 employ resources which are already present in the
2 activated sludge biomass.

3

4 The invention is limited to the embodiments
5 disclosed herein which may be varied without
6 departing from the spirit of the invention.

7

8 References

9

- 10 Andreassen, K and Neilsen, PH (1998) In situ
11 characterisation of substrate uptake by *Microthrix*
12 *parvicella* using microautoradiography. Wat. Sci.
13 Tech. 37, 19-26
14 Atlas, RM (1995). Handbook of Media for
15 Environmental Microbiology. CRC Press. Boca Raton.
16 Bibb, M. (1996) The regulation of antibiotic
17 production in *Streptomyces coelicolor* A3(2).
18 Microbiology. 142, 1335-1344.
19 Blackbeard, JR et al (1986) A survey of bulking and
20 foaming activated sludge plants in South Africa.
21 J. Water Pollut. Contr. Fed., 85, 89 - 100. Brigmon,
22 RL, Bitton, G Zam, SG and O'brien, B (1995)
23 Development and application of a monoclonal antibody
24 against *Thiothrix* spp. Applied and Environmental
25 Microbiology 13-20
26 Curragh, H, Flynn, O, Larkin, MJ, Stafford, T,
27 Hamilton, JTG and Harper, DB (1994)
28 Diversity in butane monooxygenases among butane-
29 grown bacteria. Applied and Environmental
30 Microbiology 65 (10) 4586-4593.
31 Eikelboom, DH (1968). Filamentous organisms observed
32 in activated sludge. Water Research. 9:365-388.

- 1 Eikelboom, DH (1977) Identification of filamentous
2 organisms in bulking activated sludge process. Water
3 Technol. 8 153-162
- 4 Eikelboom, DH, Andreadakis, A, and Andreassen, K,
5 (1998). Survey of filamentous populations in
6 nutrient removal plants in four European countries.
7 Water Science and Technology. 37:281-289.
- 8 Fitzpatrick, J, Fanning, L, Hearty, S, Leonard P,
9 Manning B,M, Quinn, J,G, O'Kennedy, R. (2000)
10 Applications and recent developments in the use of
11 antibodies for analysis Analytical Letters. 3 (13):
12 2563-2609
- 13 Hall, J C, O'Brien GM, Webb, S R. (1997) Phage-
14 display technology for environmental analysis.
15 Immunochemical Technology For Environmental
16 Applications ACS Symposium Series. 657: 22-37.
- 17 Haloalkane degradation and assimilation by
18 *Rhodococcus rhodochrous* NCIMB 13064. Microbiology
19 140, 1433-1442.
- 20 Hamamura, N, Storfa, RT, Semprini L and Arp DJ
21 (1999)
- 22 Heddy Zola (2000) Monoclonal Antibodies: Preparation
23 and Use of Monoclonal Antibodies and Engineered
24 Antibody Derivatives. Springer Verlag; ISBN:
25 0387915907; 1st edition.
- 26 Horinouchi, S and Beppu, T (1992). Autoregulatory
27 factors and communication in Actinomycetes. Annual
28 Review in Microbiology 46: 377-398
- 29 Knoop, S and Kunst, S (1998) Influence of
30 temperature and sludge loading on activated sludge
31 settling, especially on *Microthrix parvicella*. Water
32 Science and Technology 37 (4-5) 27-35.

- 1 Knopp, D. (1995) Application Of Immunological
2 Methods For The Determination Of Environmental-
3 Pollutants In Human Biomonitoring. *Analytica*
4 *Chimica Acta*. 311 (3): 383-392.
- 5 Kristensen, GH, Jorgensen, PE and Neilsen, PH (1994)
6 Settling characteristics of activated sludge in
7 Danish treatment plants with biological nutrient
8 removal. *Wat Sci. Technol.* 29, 157-165
- 9 Matsunaga, T, Ueki, F, Obata, K, Tajima, H, Tanaka,
10 T, Takeyama, H, Goda, Y, Fujimoto, S. (2003). Fully
11 automated immunoassay system of endocrine disrupting
12 chemicals using monoclonal antibodies chemically
13 conjugated to bacterial magnetic particles.
14 *Analytica Chimica Acta*. 475 (1-2): 75-83.
- 15 Goda, Y, Kobayashi, A, Fukuda, K, Fujimoto, S, Ike,
16 M, Fujita, M. (2000). Development of the ELISAs for
17 detection of hormone-disrupting chemicals. *Water*
18 *Science And Technology*. 42 (7-8): 81-88
- 19 Mukamolova, GV, Kaprelyants, AS, Young, DI, Young,
20 M, Kell, DB (1998) A bacterial cytokine. *Proc. Natl.*
21 *Acad. Sci. USA* 95, 8916-8921
- 22 Nodwell, J.H. and Losick, R. (1998) Purification
23 of an extracellular signalling molecule involved in
24 production of aerial mycelium by *Streptomyces*
25 *coelicolor*. *J. Bacteriol.* 180, 1334-1337.
- 26 Rao, M.B. & Deshpande, V.V. 1998. Proteases and
27 their applications in biotechnology. Dlm. Varna, A.
28 (pnyt.). *Microbes: for health, wealth and*
29 *sustainable environment*. New Delhi: Malhotra
30 Publishing House.
- 31 Reasoner, DJ, and. Geldreich EE. (1985). A new
32 medium for the enumeration and subculture of

- 1 bacteria from potable water. Applied and
2 Environmental Microbiology. 49:1-7.
- 3 Richard, MG, Jenkins, D, Hao, O and Shimizu, G (1982)
4 The isolation and characterisation of filamentous
5 microorganisms from activated sludge bulking Report
6 No. 81-2, Sanit. Engng and envir. Health res. Lab.,
7 University of California, Berkeley
- 8 Rossetti, S, Carucci, A and Rolle, E. (1994) Survey
9 on the occurrence of filamentous organisms in
10 municipal waste-water treatment plants related to
11 their operating conditions. Water Science and
12 Technology 29 (7), 305 - 308
- 13 Rossetti, S, Christensson, C, Blackall, LL and
14 Tandoi, V. (1997). Phenotypic and phylogenetic
15 description of an Italian isolate of ''Microthrix
16 parvicella''. Journal of Applied Microbiology
17 82:405-410.
- 18 Wanner, J, Ruzicková I., Jetmarová P., Krhutková O,
19 and Paraniaková J (1998). A national survey of
20 activated sludge separation problems in the Czech
21 Republic: Filaments, floc characteristics and
22 activated sludge metabolic properties. Water Science
23 and Technology. 37:271-279.

1 CLAIMS

2

3 1. A method of controlling *Microthrix parvicella*
4 proliferation in a waste treatment plant comprising
5 the step of inactivating one or more *Microthrix*
6 *parvicella* growth factors in the waste, wherein the
7 growth factors are selected from the group
8 consisting of: gamma-butyrolactone and Rpf protein.

9

10 2. A method as claimed in Claim 1 in which the or
11 each growth factors is inactivated by including in
12 the waste a bacterial isolate which uses the or each
13 growth factor as a carbon source and/or nitrogen
14 source, typically a sole carbon source.

15

16 3. A method as claimed in Claim 2 in which the
17 bacterial isolate which use gamma-butyrolactone as a
18 carbon source are selected from the group
19 comprising: bacteria including *Mycobacterium vaccae*;
20 isolated strains such as *Rhodococcus rhodochrous*
21 NCIMB 13064; and other similar strains isolated from
22 waste-water treatment systems.

23

24 4. A method as claimed in any preceding Claim in
25 which one or more of the growth factors may be
26 inactivated by adding to the waste an enzyme
27 preparation which functions to specifically cleave
28 the or each growth factor.

29

30 5. A method as claimed in Claim 4 in which the
31 enzyme preparation comprises non specific and or

1 specific microbial proteases to cleave Rpf and Rpf-
2 like proteins.

3

4 6. A method as claimed in Claim 5 in which the
5 enzyme preparation further includes esterases to
6 reverse the internal cyclic structure of the gamma-
7 butyrolactone ring and thus inactivate it.

8

9 7. A method as claimed in any preceding Claim in
10 which an antibody preparation, which includes one or
11 more antibodies which specifically target and
12 inactivate one or more of the growth factors, is
13 included in the waste being treated.

14

15 8. A method as claimed in Claim 7 in which the
16 antibody preparation includes magnetic particles to
17 which the antibodies are coupled.

18

19 9. A method as claimed in any preceding Claim in
20 which growth factors in the waste are inactivated by
21 means of chemical modification of the gamma-
22 butyrolactone ring.

23

24 10. A composition for inactivating Microthrix
25 parvicella growth factors comprising one or more
26 inactivating agents selected from the group
27 consisting of:

28 a bacterial preparation which uses the growth factor
29 as a carbon and/or nitrogen source, typically a sole
30 carbon source;

31 an enzyme preparation which specifically cleaves the
32 growth factor; and an antibody preparation which

1 specifically targets and inactivates the growth
2 factor,
3 wherein the at least one growth factor is selected
4 from the group consisting of: gamma-butyrolactone
5 and Rpf protein.

6
7 11. A composition for inactivating *Microthrix*
8 *parvicella* growth factors consisting essentially of
9 one or more inactivating agents selected from the
10 group consisting of:
11 a bacterial preparation which uses the growth factor
12 as a carbon source, typically a sole carbon source;
13 an enzyme preparation which specifically cleaves the
14 growth factor; and
15 an antibody preparation which specifically targets
16 and inactivates the growth factor,
17 wherein the at least one growth factor is selected
18 from the group consisting of: gamma-butyrolactone
19 and Rpf protein. Any combination of the above
20 mentioned inactivating agents is envisaged.

21
22 12. Use of a composition according to either Claim
23 10 or 11 in waste treatment plants to control the
24 proliferation of *Microthrix parvicella*.

INTERNATIONAL SEARCH REPORT

PCT/EP 03/07495

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C02F3/34 C07K16/12 C12N9/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C02F C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, MEDLINE, COMPENDEX, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 55624 A (YOUNG MICHAEL ;KELL DOUGLAS B (GB); UNIV WALES (GB); YOUNG DANIELL) 10 December 1998 (1998-12-10) page 3 -page 7	10,11
A	page 18 -page 19, line 36 page 23 -page 25, line 39 page 38, line 10 - line 30; claims 1-22	1-9,12
X	CURRAGH HELEN ET AL: "Haloalkane degradation and assimilation by Rhodococcus rhodochrous NCIMB 13064" MICROBIOLOGY (READING), vol. 140, no. 6, 1994, pages 1433-1442, XP001155768 cited in the application page 1439 -page 1441 --- -/--	1-12



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 October 2003

Date of mailing of the international search report

17/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Glod, G

INTERNATIONAL SEARCH REPORT

PCT/EP 03/07495

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	FUJITA MASANORI ET AL: "An enzyme-linked immunosorbent assay for detection of linear alkylbenzene sulfonate: Development and field studies" ENVIRONMENTAL SCIENCE AND TECHNOLOGY, vol. 32, no. 8, 15 April 1998 (1998-04-15), pages 1143-1146, XP002259489 ISSN: 0013-936X abstract -----	1-12
A	TANAKA T ET AL: "Fully automated chemiluminescence immunoassay of insulin using antibody-protein A-bacterial magnetic particle complexes." ANALYTICAL CHEMISTRY. UNITED STATES 1 AUG 2000, vol. 72, no. 15, 1 August 2000 (2000-08-01), pages 3518-3522, XP002259490 ISSN: 0003-2700 abstract -----	8

INTERNATIONAL SEARCH REPORT

PCT/EP 03/07495

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9855624	A	10-12-1998	AU	749414 B2	27-06-2002
			AU	7779798 A	21-12-1998
			EP	0983361 A1	08-03-2000
			WO	9855624 A1	10-12-1998
			JP	2002503106 T	29-01-2002
			NZ	501568 A	30-11-2001
			ZA	9804838 A	04-03-2000